Article Sidebar

Published: 2021-12-09
Abstract Views: 173
DOI: https://doi.org/10.52163/yhc.v62i7%20(2021).203
Issue
Vol. 62 No. 7 (2021)
Section
Articles
How to Cite
Lỷ, T. T. ., Thanh, L. Q. ., Mãi, Đỗ V. ., & Chi, B. Đặng P. . (2021). CHARACTERISTICS OF NEPHROTOXICITY IN PATIENTS USING VANCOMYCIN. Vietnam Journal of Community Medicine, 62(7 (2021). https://doi.org/10.52163/yhc.v62i7 (2021).203

CHARACTERISTICS OF NEPHROTOXICITY IN PATIENTS USING VANCOMYCIN

Tran Thi Ly1, Le Quang Thanh2, Do Van Mai3, Bui Dang Phuong Chi4
1 Tan Thanh Medical Center
2 Tu Du Hospital
3 Tay Do University
4 University of Medicine Pham Ngoc Thach

Main Article Content

Abstract

Objectives: To describe the nephrotoxicity characteristics in patients using vancomycin at An Giang Obstetrics and Children’s Hospital. Subjects and methods: Retrospective cohort study on 100 medical records of patients treated at An Giang Obstetrics and Children’s Hospital during the period from January 1st, 2020 to December 31st, 2020. Results: The rate of nephrotoxicity in the study was 24.0%. Median time to toxicity onset was 8 days, interquartile range 4-14 days from drug initiation. The rate of occurrence of nephrotoxicity at different levels: risk, damage and failure were 54.2%, 29.2% and 16.6%, respectively. 33.3% of patients who developed nephrotoxicity had reversible toxicity with a median time to toxicity recovery of 5.2 (3.2 - 14.8) days after the end of dosing. Conclusion: The rate of nephrotoxicity in the study was 24.0%. The rate of occurrence of nephrotoxicity at different levels: risk, damage and failure were 54.2%, 29.2% and 16.6%, respectively. 33.3% of patients with nephrotoxicity had reversible toxicity.

Article Details

Keywords

Vancomycin, nephrotoxicity.

References

1. Stefano C, Maya H, Hakim K et al., New Rcgimen for Continuous Infusion of Vancomycin in Critically 111 Patients, Antimicrob Agenís Chemother, 2016; 60(8): 4750-6.
2. Davey P, Wilcox MH, Antimicrobial Chemotherapy, 7th edition. Oxtord Univcrsity Press, USA, 2015.
3. Timothy H, Tony W, Jeffrey L et al., Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous vcrsus intcrmittcnt infusion, lnt J Antimicrob Agents, 2015; 46(3): 249-53.
4. Yong PC, Song MM, Kyung MB et al., Treatment Duration for Uncomplicated Staphylococcus aureus Bacteremia To Prevent Relapse: Analysis of a Prospective Observational Cohort Study, Antimicrobial Agents and Chemotherapy, 2013; 57(3): 1150–1156.
5. Christopher PK, Grant SF, Kristina ER et al., Comparative prognostic accuracy of sepsis scores for hospital mortality in adults with suspected infection in non-ICU and ICU at an academic public hospital, Plos one, 2019; 1-16.
6. Levita KH, Donald IH, Ryan Q et al., High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections, Efficacy and Toxicity, Arch Intern Med, 2006; 166: 2138-2144.
7. Pan K, Chen C, Chen Z et al., Vancomycin Associated Acute Kidney Injury: A Longitudinal Study in China, Frontiers in Pharmacology, 2021; 12: 1-9.
8. Shigehiko U, Louise C, Hiroshi M et al., Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution, Intensive Care Med, 2002; 28: 1664–1667.